BOSTON - Pyxis Oncology, Inc. (NASDAQ:PYXS) announced preliminary data from ongoing Phase 1 clinical studies of its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with ...

Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...

Pyxis Oncology ( (PYXS)) has provided an announcement. On December 18, 2025, Pyxis Oncology reported positive preliminary Phase 1 data for its first-in-concept antibody-drug conjugate MICVO in ...

Jesse Calis spent a month with the Blackmagic PYXIS 12K cinema camera. His verdict: “If you are a serious filmmaker… this camera is really for you.” And how. Watch his full review of the Blackmagic ...

Investing.com -- Pyxis Oncology Inc (NASDAQ:PYXS) stock tumbled 49.9% in premarket trading Thursday after investors expressed disappointment with preliminary data from the company’s experimental ...

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...

William Blair analyst Andy Hsieh reiterated a Hold rating on Pyxis Oncology today. The company’s shares closed last Thursday at $1.72, close to its 52-week low of $0.99. According to TipRanks.com, ...

As far as taking care of my body goes, I'm not exactly low maintenance. I regularly lift weights and try to get in pilates when I can, and I aim to eat a balanced diet. But in spite of this, I still ...

The following slide deck was published by Pyxis Oncology, Inc. in conjunction with this event.

Here’s a look back at the tools and accessories that helped shape coffee preparation, service and enjoyment in 2025.